Abcentra


Abcentra is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for cardiovascular inflammation, particularly targeting oxidized LDL to treat coronary artery disease and related conditions. Their mission is to bring new and better treatment options to patients with coronary artery disease, aiming to prevent heart attacks and improve cardiovascular health. The company focuses on developing a new class of pharmaceutical treatments that are highly differentiated from current options, leveraging knowledge of inflammation's role in heart disease.

Industries

biotechnology
health-care
medical
therapeutics

Nr. of Employees

small (1-50)

Abcentra

Los Angeles, California, United States, North America


Products

Clinical-stage anti-oxidized LDL monoclonal antibody

A clinical-stage, fully human IgG1 monoclonal antibody directed to a defined epitope on oxidized LDL / apolipoprotein B-100, developed to reduce plaque-associated inflammation and modulate vascular immune responses.


Services

Collaborative clinical research partnerships

Engages with diagnostic providers, academic investigators and clinical sites to run interventional studies and integrate imaging- and AI-based endpoints into study designs.

Expertise Areas

  • Clinical trial management
  • Monoclonal antibody therapeutics
  • Cardiovascular inflammation and atherosclerosis
  • Imaging biomarker development and application
  • Show More (5)

Key Technologies

  • Fully human IgG1 monoclonal antibody therapeutics
  • Epitope-specific antibody targeting (oxidized LDL / apoB-100)
  • Computed tomography-derived perivascular fat attenuation index (FAI/PCAT)
  • AI-driven cardiac CT image analysis
  • Show More (4)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.